Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec, Pfizer Form Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Evotec, Pfizer Form Pact

License and collaboration agreement in tissue fibrosis

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Evotec AG has signed an agreement on a four-year research collaboration with Pfizer Inc. in the field of tissue fibrosis.

Under the terms of this license and collaboration agreement, scientists at Evotec and Pfizer will explore potential novel mechanisms as targeted anti-fibrotics in multi-organ fibrosis. Evotec will contribute its drug discovery platform whereas Pfizer will provide key technologies and industrial scope as well as pharmaceutical development and marketing expertise.

Financial terms of the collaboration include an upfront payment and potential milestone payments from Pfizer based on the achievement of specific development and sales milestones.

“We are proud about Pfizer partnering with us in our growing initiative in the fibrosis field utilizing one of our internal programs,” said Cord Dohrmann, chief scientific officer, Evotec.

Charles MacKay, chief scientific officer, inflammation and immunology at Pfizer, said, “We believe that Evotec’s discovery platform is well-positioned to deliver potentially innovative approaches to several areas of tissue fibrosis.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics